BeiGene, Ltd. (BGNE), a clinical-stage pharmaceutical company, announced Wednesday that the U.S. Food and Drug Administration has accepted for review its supplemental new drug application or sNDA for BRUKINSA (zanubrutinib) in combination with obinutuzumab as a treatment for relapsed or refractory follicular lymphoma.